Intech Biopharm (ROCO:6461) Total Liabilities: NT$1,250.0 Mil (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ROCO:6461 Intech Biopharm Ltd ROCO:6461
55 GF Score
Price NT$15.45
GF Value NT$87.90
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Intech Biopharm Total Liabilities?

Intech Biopharm ROCO:6461 -0.64% 55 Total Liabilities is NT$1,250.0 Mil as of Dec. 2025. GuruFocus rates ROCO:6461 with a GF Score™ of 55/100 and a GF Value™ of NT$87.90 (Possible Value Trap). The stock has 6 warning signs investors should review.

Intech Biopharm's Total Liabilities for the quarter that ended in Dec. 2025 was NT$1,250.0 Mil.

Intech Biopharm's quarterly Total Liabilities declined from Jun. 2025 (NT$1,599.12 Mil) to Sep. 2025 (NT$1,508.59 Mil) and declined from Sep. 2025 (NT$1,508.59 Mil) to Dec. 2025 (NT$1,249.97 Mil).

Intech Biopharm's annual Total Liabilities increased from Dec. 2023 (NT$1,543.22 Mil) to Dec. 2024 (NT$1,581.52 Mil) but then declined from Dec. 2024 (NT$1,581.52 Mil) to Dec. 2025 (NT$1,249.97 Mil).

Intech Biopharm Total Liabilities Historical Data

* Premium members only.

The historical data trend for Intech Biopharm's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Intech Biopharm Total Liabilities Chart

Intech Biopharm Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1,263.99 1,518.79 1,543.22 1,581.52 1,249.97

Intech Biopharm Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Total Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,581.52 1,644.34 1,599.12 1,508.59 1,249.97
ROCO:6461
55GF Score
Intech Biopharm Ltd ROCO:6461
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Intech Biopharm Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Intech Biopharm's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=243.324+(995.499+10.299
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0.847+0)
=1,250.0

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=2350.952-1100.983
=1,250.0

Intech Biopharm's Total Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=243.324+(995.499+10.299
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0.847+0)
=1,250.0

Total Liabilities=Total Assets (Q: Dec. 2025 )-Total Equity (Q: Dec. 2025 )
=2350.952-1100.983
=1,250.0

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of NT$1,250.0 Mil mean?
Intech Biopharm (ROCO:6461) has a Total Liabilities of NT$1,250.0 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Intech Biopharm and its competitors.
Is Intech Biopharm's Total Liabilities too high?
Intech Biopharm's current Total Liabilities is NT$1,250.0 Mil. Overall, Intech Biopharm has a GF Score™ of 55/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Intech Biopharm's Total Liabilities compare to VRTX and REGN?
Intech Biopharm's Total Liabilities of NT$1,250.0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Intech Biopharm and its competitors. Intech Biopharm's current Total Liabilities is NT$1,250.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intech Biopharm stock overvalued right now?
Based on GuruFocus' analysis, Intech Biopharm (ROCO:6461) is currently considered Possible Value Trap. The stock's GF Value™ is NT$87.90, compared to a current price of NT$15.45 — trading 82.4% below its estimated fair value. The current Total Liabilities is NT$1,250.0 Mil. Intech Biopharm's overall GF Score™ is 55/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Intech Biopharm (ROCO:6461), the current Total Liabilities is NT$1,250.0 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Intech Biopharm (ROCO:6461) Overvalued in 2026?

Based on GuruFocus' analysis, Intech Biopharm stock appears to be undervalued. The current stock price of NT$15.45 is trading 82.4% below its estimated GF Value™ of NT$87.90. GuruFocus considers Intech Biopharm to be Possible Value Trap.

Key valuation signals for ROCO:6461:

  • Total Liabilities: NT$1,250.0 Mil
  • GF Value™: NT$87.90 vs. price of NT$15.45 (82.4% below fair value)
  • GF Score™: 55/100 with 6 warning signs

No single metric tells the full story. See the ROCO:6461 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Intech Biopharm Business Description

Address No.36, Ruiguang Road, 3rd Floor, Lane 358, Neihu District, Taipei, TWN, 114
Intech Biopharm Ltd is engaged in pharmaceutical R&D and sales. The company focuses on the development and manufacturing of new combinations, new formulations, and generic drugs with high barriers for the treatment of respiratory diseases. It owns the patented MDI platform iLEF (Inhaled Low Ethanol Formulation). The company operates in a single-industry segment, mainly engaged in R&D of technology and sale of pharmaceuticals.
55GF Score

Get the complete analysis for ROCO:6461

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$15.45
Price
NT$87.90
GF Value